Peer reviewed
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men
Randomized, double-blind trial (Dollerup et al.) showing that NR safely increased blood NAD+ in obese men but did not improve insulin sensitivity or body composition over 12 weeks, illustrating the biomarker-vs-outcome gap.
American Journal of Clinical NutritionPublished May 9, 2018Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- American Journal of Clinical Nutrition
- Source type
- Peer reviewed
- Registry ID
dollerup-2018-nr-human
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.